Regulatory and quality due diligence for acquiring med-tech companies is often overlooked.
In medtech/ biotech, organic expansion is dwindling and acquisition is the preferred growth mechanism. More and more large organizations are scooping up nascent companies in order to expand existing portfolios or enter new markets. Most of these buys are happening when a start-up is no longer a start-up but a viable, post-revenue generating company with meaningful valuation and actual, realized value.
This type of opportunity makes investors – private, VCs and corporate strategics alike – salivate and eager to get their hands on these “shiny, new toys.” For the most part, these acquisitions are preceded by deep due diligence that involves vetting the founders and team, product, market, advisors, strategic decisions as well as a through review of the financials. As one investor friend told me once: “We see them in their underwear.”
However, the due-diligence often fails in adequately assessing a company’s regulatory and quality “health” leading to more painful and expensive navigation of FDA and EU submissions downstream. This – along with inadequate quality management system readiness – sometimes leads to a company requiring more capital than previously anticipated.
Here are some tips to ensure that your investment in a company isn’t derailed by regulatory or quality unpreparedness:
- Obtain multiple opinions and position statements on the company’s regulatory strategy.
- Having a robust network of regulatory consultants in your rolodex is critical but make sure to leverage several of them when determining the soundness of a company’s regulatory approach. There is an example I recall when a venture group called me after a product’s 510(k) was refused for several reasons. I immediately recognized the product as having an FDA Guidance for Manufacturers that allowed the company to submit a limited set of testing data as long as it complied with the guidance. This ultimately could have saved the company – and investors – hundreds of thousands of dollars. This occurred because they only considered one third party opinion and this “expert” did not confirm existence of a guidance document. Multiple opinions may cost a bit more in the short term but the outcome of bad advice can be costly in the long run! Hedge your bets – call on a conglomerate of consultants vs. a single expert!
- If a company already has a product on the market, have a consultant perform a quality management system gap analysis prior to acquisition.
- This is probably one of the biggest financial obstacle that investors fail to predict in advance- and frankly, aren’t even aware of in the first place! Getting a product to market- while a significant step and financial hurdle – is not the complete regulatory story. Once on the market in the US, for example, a company must follow what the FDA calls “General Controls” which includes a quality management system per 21 CFR 820 (and EN ISO 13485:2012 in EU). Implementation of a full QMS capable of withstanding FDA and notified body audits/ inspections can be expensive: on average, a consulting firm’s fee can range from $20k (simple device, low risk) to $100k+ (complex device, high risk) for QMS implementation. I can’t count on two hands the number of investors who have asked me: “What the heck is a quality management system?”. Know about a QMS and anticipate future financial commitment to ensuring the company has a robust QMS in place.
- Evaluate quality and regulatory resources at the target company.
- Pop quiz: who is the most important person in an early stage company? A) CEO B) CEO or C) CEO? The answer is – none of these. Yes, the C-level team is critical for fund raising, operations, and all other elements that are critical for emerging companies. But folks like the VP of Regulatory and VP of Quality are just – if not more – important than them! They are key personnel that can dictate a product’s approval status, continued on-market status and maintain knowledge of the regulatory climate associated with the company’s product lines. I served as a de-facto VP a few years back at a cardiac company where the previous VP of Regulatory failed to perform simple tasks like site registration and implement a QMS; this company was issued a warning letter by the FDA and had to cease operations for a few months while they responded to the deficiencies! Grill the quality/ regulatory representatives in your prospective investment newco to determine readiness for handling future needs!
- Perform a regulatory landscape of predicate and competitor products of the company.
- The regulatory climate – particulary in the US – shifts frequently. A medical device or drug with a track record of minimal field actions or reportable events (deaths, serious injury, etc.) can fall under further scrutiny after a serious post-market event – overnight! Breast implants were not even on the FDA’s radar when they were first developed until they became a huge hot topic after a rash of adverse events. Before you sink your dollars into a company, perform a regulatory landscape that includes more than just the regulatory strategy. Research competitor products, MDRs (Medical Device Reports), guidance documents, issued warning letters and other post-market information!
Regulatory and quality obstacles can present huge hurdles for medtech companies seeking to go to or remain in the market. Investors can reap significant rewards by investing in the right companies but distinguishing a right company from a lost cause involves a lot more due diligence on the regulatory front than most groups are performing. Invest in respected consultants on the front-end and save yourself from the trouble on the back end.